logo

For the Inventor, By the Inventor

Newark, CA, United States of America

Teneobio, Inc.

Calculating rank
USPTO Granted Patents = 15


Forward Citations = 11

Loading Chart...
Loading Chart...

30 inventors (with patents filed for the assignee):

goldMedal Nathan D Trinklein (14 out of 23 patents)

silverMedal Katherine Harris (12 out of 17 patents)

bronzeMedal Shelley Force Aldred (9 out of 18 patents)

4.  Wim Van Schooten (9 out of 19 patents)

5.  Kevin Dang (3 out of 3 patents)

6.  Duy Pham (2 out of 5 patents)

7.  Udaya Rangaswamy (2 out of 2 patents)

8.  Harbani Kaur Malik Chaudhry (2 out of 3 patents)

9.  Brian Avanzino (2 out of 2 patents)

10.  Karen Chang (2 out of 2 patents)

11.  Nicole Allen (2 out of 2 patents)

12.  Ute Schellenberger (1 out of 3 patents)

13.  Omid Vafa (1 out of 3 patents)

14.  Starlynn Clarke (1 out of 3 patents)

15.  James Noble Kochenderfer (1 out of 30 patents)


15 patents:

1. 12747298 - MULTI-SPECIFIC ANTIBODIES BINDING TO BCMA (2026-09-29),
2. 12735503 - ANTI-MUC1-C ANTIBODIES AND CAR-T STRUCTURES (2026-09-15),
3. 12709644 - ANTI-CD20 ANTIBODIES AND CAR-T STRUCTURES (2026-08-18),
4. 12590163 - AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE (2026-03-31),
5. 12570717 - ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS (2026-03-10),
6. 12495776 - TRANSGENIC NON-HUMAN ANIMALS PRODUCING MODIFIED HEAVY CHAIN-ONLY ANTIBODIES (2025-12-16),
7. 12371505 - Anti-BCMA heavy chain-only antibodies (2025-07-29),
8. 12180298 - Heavy chain antibodies binding to PSMA (2024-12-31),
9. 11970540 - Anti-BCMA heavy chain-only antibodies (2024-04-30),
10. 11905326 - Multispecific heavy chain antibodies binding to CD22 and CD3 (2024-02-20),
11. 11884735 - Agonistic anti-IL-2R antibodies and methods of use (2024-01-30),
12. 11873336 - Heavy chain antibodies binding to CD22 (2024-01-16),
13. 11613572 - CD3 binding antibodies (2023-03-28),
14. 11505606 - CD3 binding antibodies (2022-11-22),
15. 11434299 - Anti-BCMA heavy chain-only antibodies (2022-09-06),
Company Overview
Teneobio, Inc. is a biotechnology company based in Newark, California, specializing in the development of innovative therapeutic antibodies. The organization focuses on creating next-generation antibody formats that enhance the efficacy and safety of treatments for various diseases, including cancer and autoimmune disorders. Teneobio leverages its proprietary technology platform to design and optimize these biologics, aiming to address unmet medical needs and improve patient outcomes through advanced therapeutic solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

15 Patents

#29 in Newark, CA

#5,037 in California

#21,085 in US

#39,991 in the World

Newark, CA (US)
Newark, CA, United States of America

Teneobio, Inc.

Forward Citations = 11

30 inventors:

goldMedal Nathan D Trinklein (14 out of 23 patents)

silverMedal Katherine Harris (12 out of 17 patents)

bronzeMedal Shelley Force Aldred (9 out of 18 patents)

4.  Wim Van Schooten (9 out of 19 patents)

5.  Kevin Dang (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Teneobio, Inc.. Retrieved from https://idiyas.com/company/teneobio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…